Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMF30HL)

Drug Name
Zarnestra Drug Info
Synonyms
JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
159324
ChEBI ID
CHEMBL289228
CAS Number
CAS 192185-72-1
TTD Drug ID
D07NPS
VARIDT Drug ID
DR00414

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Tryptophan metabolism 2.23 0.00e+0 35/42 (83.33%) CYP1B1;MAOB;AOX1;...
Valine, leucine and isoleucine degradation 2.22 0.00e+0 42/48 (87.5%) HMGCS1;ABAT;AOX1;...
Peroxisome 2.22 0.00e+0 72/82 (87.8%) ACOX2;IDH1;PHYH;...
Propanoate metabolism 2.07 1.97e-3 30/34 (88.24%) ABAT;DLD;ACAT1;...
Histidine metabolism 2.05 4.72e-3 16/22 (72.73%) MAOB;HNMT;AOC1;...
Fatty acid elongation 1.82 1.97e-2 19/27 (70.37%) HADHB;ACOT7;ACAA2;...
Glycine, serine and threonine metabolism 1.80 2.13e-2 31/40 (77.5%) GATM;MAOB;PSAT1;...
Metabolism of xenobiotics by cytochrome P450 1.79 2.16e-2 49/77 (63.64%) CYP1B1;CYP2E1;ADH1B;...
Arginine and proline metabolism 1.75 2.36e-2 39/50 (78%) GATM;MAOB;ARG2;...
Fatty acid degradation 1.75 2.12e-2 40/43 (93.02%) ACAT1;ECI2;ADH1B;...
Butanoate metabolism 1.74 2.36e-2 23/28 (82.14%) HMGCS1;ABAT;ACAT1;...
Pyruvate metabolism 1.70 3.15e-2 41/47 (87.23%) DLD;PCK2;ACAT1;...
Terpenoid backbone biosynthesis 1.69 3.51e-2 18/22 (81.82%) HMGCS1;GGPS1;HMGCR;...
Primary bile acid biosynthesis 1.67 3.71e-2 15/17 (88.24%) ACOX2;HSD17B4;AMACR;...
Retinol metabolism 1.67 3.51e-2 41/68 (60.29%) RDH11;ALDH1A1;AOX1;...
beta-Alanine metabolism 1.66 3.49e-2 25/30 (83.33%) ABAT;DPYS;EHHADH;...
Steroid hormone biosynthesis 1.63 4.49e-2 43/61 (70.49%) CYP1B1;SRD5A1;CYP2E1;...
Steroid biosynthesis 1.62 4.59e-2 19/20 (95%) MSMO1;SC5D;DHCR24;...
Complement and coagulation cascades -1.65 4.54e-2 76/85 (89.41%) C4BPA;F13A1;CFB;...
NF-kappa B signaling pathway -1.65 4.69e-2 90/104 (86.54%) VCAM1;RIPK1;BTK;...
Influenza A -1.66 4.68e-2 156/172 (90.7%) IFNAR2;IFIH1;TNFRSF1A;...
Bladder cancer -1.66 4.85e-2 40/41 (97.56%) RB1;FGFR3;E2F3;...
Malaria -1.70 3.19e-2 44/50 (88%) GYPB;CD40LG;CSF3;...
Systemic lupus erythematosus -1.72 2.36e-2 45/135 (33.33%) TRIM21;HLA-DMB;SNRPB;...
Type I diabetes mellitus -1.72 2.43e-2 38/43 (88.37%) HLA-DMB;IL1B;HLA-DPA1;...
Viral protein interaction with cytokine and cytokine re... -1.74 2.20e-2 84/100 (84%) TNFRSF1B;CCR5;CCL5;...
Tuberculosis -1.74 2.27e-2 159/180 (88.33%) PLK3;ATP6V0C;CYP27B1;...
Epstein-Barr virus infection -1.75 2.43e-2 189/202 (93.56%) IFNAR2;RIPK1;RBPJL;...
TNF signaling pathway -1.77 1.68e-2 103/112 (91.96%) TNFRSF1B;CCL5;BIRC3;...
Phagosome -1.78 1.72e-2 118/152 (77.63%) HLA-A;ATP6V1E1;ATP6V1B1;...
Toll-like receptor signaling pathway -1.83 7.72e-3 94/104 (90.38%) IFNAR2;RIPK1;MAPK9;...
Antigen processing and presentation -1.86 3.64e-3 60/78 (76.92%) TAP1;HLA-DMB;KLRD1;...
Herpes simplex virus 1 infection -1.90 4.04e-3 165/498 (33.13%) CCL5;HCFC1;BIRC3;...
Chagas disease -1.92 3.03e-3 93/102 (91.18%) CCL2;PPP2R2A;NFKB1;...
Legionellosis -2.01 1.73e-3 51/57 (89.47%) ARF1;CLK4;HSPA2;...
Neutrophil extracellular trap formation -2.04 2.02e-3 101/189 (53.44%) CR1;PADI4;SELPLG;...
Rheumatoid arthritis -2.06 2.43e-3 78/93 (83.87%) IL1B;CTSL;TNFSF13;...
Pertussis -2.10 0.00e+0 64/76 (84.21%) IL1B;MYD88;TRAF6;...
IL-17 signaling pathway -2.20 0.00e+0 84/94 (89.36%) CCL2;NFKB1;TRAF3IP2;...
Leishmaniasis -2.41 0.00e+0 67/77 (87.01%) NFKB1;HLA-DMB;IL1B;...
Staphylococcus aureus infection -2.44 0.00e+0 72/95 (75.79%) KRT10;HLA-DMB;CAMP;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 10uM 6H
SK-ES-1 CVCL_0627 Homo sapiens 0.5uM - 4uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 0.5uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 0.5uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 0.5uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 10uM 6H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 10uM 6H
MDST8 CVCL_1400 Homo sapiens 10uM 6H
NCI-H508 CVCL_1561 Homo sapiens 10uM 6H
SNU-1040 CVCL_5001 Homo sapiens 10uM 6H
SNU-407 CVCL_5004 Homo sapiens 0.5uM - 10uM 24H
SNU-C4 CVCL_5008 Homo sapiens 10uM 6H
SNU-C5 CVCL_5009 Homo sapiens 10uM 6H
SW480 CVCL_0546 Homo sapiens 10uM 6H
SW620 CVCL_0547 Homo sapiens 10uM 6H
SW948 CVCL_0550 Homo sapiens 10uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 10uM 6H
HT115 CVCL_1294 Homo sapiens 10uM 6H
RKO CVCL_0504 Homo sapiens 10uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 0.5uM - 10uM 6H, 24H
HEC-1-A CVCL_0293 Homo sapiens 0.5uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 0.5uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 0.5uM - 10uM 24H
SNG-M CVCL_1707 Homo sapiens 10uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 0.5uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 0.5uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
DV-90 CVCL_1184 Homo sapiens 10uM 6H
NCI-H1573 CVCL_1483 Homo sapiens 0.5uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 0.5uM - 10uM 24H
SK-LU-1 CVCL_0624 Homo sapiens 10uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 10uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 10uM 6H
T3M-10 CVCL_1729 Homo sapiens 10uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 0.5uM - 10uM 24H
HCC15 CVCL_1253 Homo sapiens 10uM 6H
HCC95 CVCL_1276 Homo sapiens 0.5uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 10uM 6H
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 10uM 6H
NCI-H2110 CVCL_1529 Homo sapiens 0.5uM - 10uM 24H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 10uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 10uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 10uM 6H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 0.5uM - 10uM 24H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 10uM 6H
OV7 CVCL_1623 Homo sapiens 10uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 0.5uM - 10uM 24H
RMG-I CVCL_1663 Homo sapiens 10uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 10uM 6H
RMUG-S CVCL_1666 Homo sapiens 10uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 6H, 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 10uM 6H
PL-21 CVCL_2161 Homo sapiens 10uM 6H
SKM-1 CVCL_0010 Homo sapiens 10uM 6H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 0.5uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 0.5uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 0.5uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 0.5uM - 10uM 24H
SK-MEL-1 CVCL_0523 Homo sapiens 10uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 10uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 10uM 6H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 0.5uM - 4uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 0.5uM - 10uM 24H